Diabetic retinopathy is a major cause worldwide of vision loss from diabetic maculopathy or proliferative retinopathy. Without widely accepted classifications of diabetic retinopathy and diabetic maculopathy, it is difficult to compare results of clinical trials or monitor clinical care. The European School of Advanced Studies in Ophthalmology has developed an international classification of diabetic maculopathy based upon spectral domain optical coherence tomography, which could be helpful for both initial evaluation and subsequent follow-up of diabetic patients in both clinical practice and experimental trials.
GoldbergMFJampolLM.Knowledge of diabetic retinopathy before and 18 years after the Airlie House Symposium on Treatment of Diabetic Retinopathy. Ophthalmology1987; 94(7): 741–746.
2.
Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology1991; 98(5 Suppl.): 786–806.
3.
WilkinsonCPFerrisFL3rdKleinRE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology2003; 110(9): 1677–1682.
4.
BresslerNMOdiaIMaguireM, et al. Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: a post hoc analysis of the Protocol T Randomized Clinical Trial. JAMA Ophthalmol. Epub ahead of print 27 June 2019. DOI: 10.1001/jamaophthalmol.2019.1963.
5.
DeakGGSchmidt-ErfurthUMJampolLM.Correlation of central retinal thickness and visual acuity in diabetic macular edema. JAMA Ophthalmol2018; 136(11): 1215–1216.
6.
PanozzoGParoliniBGussonE, et al. Diabetic macular edema: an OCT-based classification. Semin Ophthalmol2004; 19(1–2): 13–20.
